Sai Parenterals Limited (SAIPARENT) — Financial Results

1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Sai Parenterals reported robust financial performance for Q4 and FY26, with revenue surging 166.65% YoY to ₹197.93 crores in Q4FY26 and 140.37% YoY to ₹380.99 crores for the full year, driven by CDMO exports and Australian subsidiary integration. PAT grew 736.04% QoQ to ₹13.25 crores in Q4FY26, while EBITDA rose 366.79% QoQ to ₹28.97 crores, reflecting strong margin expansion and operational leverage. The company completed its IPO in March 2026, raised ₹285 crores, and plans ₹440 crores of capex through FY27 for capacity expansion and R&D, targeting ₹750 crores revenue by FY27.

2 Financial Results 🔴 High Importance Neutral 📄 PDF

Sai Parenterals Limited announced its Q4 and FY 2025-26 earnings conference call scheduled for May 27, 2026 at 4:00 pm IST in Hyderabad, following the release of audited results for the quarter and year ended March 31, 2026, which are available on its website.

📊 Stock Analysis — SAIPARENT ✨ Ask AI About This